A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis

Vaccine

Volumn 32, Issue 31, 2014, Pages 3917-3926

  Wu, Fei ^a   Fan, Xingjuan ^a   Yue, Yan ^a   Xiong, Sidong ^a   Dong, Chunsheng ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Coxsackievirus B3; Dendritic cell; Mucosal vaccine; Polyfunctional T cells; Vesicular stomatitis virus; Viral myocarditis

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHITOSAN; CREATINE KINASE; CREATINE KINASE MB; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; PROTEIN VP1; SECRETORY IMMUNOGLOBULIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS BASED MUSCOSAL VACCINE; VIRUS VACCINE; VIRUS VECTOR; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; COXSACKIE VIRUS B3; CREATINE KINASE BLOOD LEVEL; CYTOKINE RELEASE; CYTOPLASM; CYTOTOXICITY; DENDRITIC CELL; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HEART EJECTION FRACTION; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MESENTERY LYMPH NODE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PARALYSIS; PLAQUE FORMING CELL; POLYFUNCTIONAL T CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; T LYMPHOCYTE; TREMOR; VESICULAR STOMATITIS VIRUS; VIRUS MYOCARDITIS; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELLULAR IMMUNITY; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS; IMMUNOLOGY; LYMPH NODE; MYOCARDITIS; VESICULOVIRUS; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; COXSACKIEVIRUS INFECTIONS; DENDRITIC CELLS; ENTEROVIRUS B, HUMAN; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; LYMPH NODES; MALE; MICE, INBRED BALB C; MYOCARDITIS; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VESICULOVIRUS; VIRAL FUSION PROTEINS; VIRAL VACCINES;

EID: 84902005673     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.052     Document Type: Article

References (54)

1. Feldman A.M., McNamara D. Myocarditis. N Engl J Med 2000, 343:1388-1398.
2. Woodruff J.F. Viral myocarditis: a review. Am J Pathol 1980, 101:425-484.
3. Pauschinger M., Phan M.D., Doerner A., Kuehl U., Schwimmbeck P.L., Poller W., et al. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 1999, 99:889-895.
4. Tam P.E. Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol 2006, 19:133-146.
5. Racaniello V.R. Picornaviridae: the virus and their replication. Fields virology 2007, Lippincott Williams &Wilkins, Philadelphia, PA. 5th ed. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, S.E. Straus, M.A. Martin, B. Roizman (Eds.).
6. Henke A., Wagner E., Whitton J.L., Zell R., Stelzner A. Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization. J Virol 1998, 72:8327-8331.
7. Henke A., Zell R., Stelzner A. DNA vaccine-mediated immune responses in Coxsackie virus B3-infected mice. Antiviral Res 2001, 49:49-54.
8. Kim J.Y., Jeon E.S., Lim B.K., Kim S.M., Chung S.K., Kim J.M., et al. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge. Vaccine 2005, 23:1672-1679.
9. Werner S., Klump W.M., Schonke H., Hofschneider P.H., Kandolf R. Expression of coxsackievirus B3 capsid proteins in Escherichia coli and generation of virus-specific antisera. DNA 1988, 7:307-316.
10. Beck M.A., Chapman N.M., McManus B.M., Mullican J.C., Tracy S. Secondary enterovirus infection in the murine model of myocarditis. Pathologic and immunologic aspects. Am J Pathol 1990, 136:669-681.
11. Chapman N.M., Ragland A., Leser J.S., Hofling K., Willian S., Semler B.L., et al. A group B coxsackievirus/poliovirus 5' nontranslated region chimera can act as an attenuated vaccine strain in mice. J Virol 2000, 74:4047-4056.
12. Fohlman J., Ilback N.G., Friman G., Morein B. Vaccination of Balb/c mice against enteroviral mediated myocarditis. Vaccine 1990, 8:381-384.
13. See D.M., Tilles J.G. Efficacy of a polyvalent inactivated-virus vaccine in protecting mice from infection with clinical strains of group B coxsackieviruses. Scand J Infect Dis 1994, 26:739-747.
14. Xu W., Shen Y., Jiang Z., Wang Y., Chu Y., Xiong S. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 2004, 22:3603-3612.
15. Zhang H., Morgan-Capner P., Latif N., Pandolfino Y.A., Fan W., Dunn M.J., et al. Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain. Am J Pathol 1997, 150:2197-2207.
16. Zhang L., Parham N.J., Zhang F., Aasa-Chapman M., Gould E.A., Zhang H. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis. Vaccine 2012, 30:2301-2308.
17. Hertel N.T., Pedersen F.K., Heilmann C. Coxsackie B3 virus encephalitis in a patient with agammaglobulinaemia. Eur J Pediatr 1989, 148:642-643.
18. Mena I., Perry C.M., Harkins S., Rodriguez F., Gebhard J., Whitton J.L. The role of B lymphocytes in coxsackievirus B3 infection. Am J Pathol 1999, 155:1205-1215.
19. Geller T.J., Condie D. A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin. J Neurol Sci 1995, 129:131-133.
20. Rahnefeld A., Ebstein F., Albrecht N., Opitz E., Kuckelkorn U., Stangl K., et al. Antigen-presentation capacity of dendritic cells is impaired in ongoing enterovirus myocarditis. Eur J Immunol 2011, 41:2774-2781.
21. Yuan J., Yu M., Lin Q.W., Cao A.L., Yu X., Dong J.H., et al. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol 2010, 185:4004-4010.
22. Lichty B.D., Power A.T., Stojdl D.F., Bell J.C. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 2004, 10:210-216.
23. Roberts A., Buonocore L., Price R., Forman J., Rose J.K. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 1999, 73:3723-3732.
24. Lawson N.D., Stillman E.A., Whitt M.A., Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc Nat Acad Sci USA 1995, 92:4477-4481.
25. Whelan S.P., Ball L.A., Barr J.N., Wertz G.T. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Nat Acad Sci USA 1995, 92:8388-8392.
26. Haglund K., Leiner I., Kerksiek K., Buonocore L., Pamer E., Rose J.K. High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J Virol 2002, 76:2730-2738.
27. Johnson J.E., Schnell M.J., Buonocore L., Rose J.K. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J Virol 1997, 71:5060-5068.
28. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001, 106:539-549.
29. Tan G.S., McKenna P.M., Koser M.L., McLinden R., Kim J.H., McGettigan J.P., et al. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology 2005, 331:82-93.
30. Faber M., Lamirande E.W., Roberts A., Rice A.B., Koprowski H., Dietzschold B., et al. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol 2005, 86:1435-1440.
31. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 2005, 340:174-182.
32. Buonocore L., Blight K.J., Rice C.M., Rose J.K. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol 2002, 76:6865-6872.
33. Ezelle H.J., Markovic D., Barber G.N. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J Virol 2002, 76:12325-12334.
34. Cobleigh M.A., Wei X., Robek M.D. A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice. J Virol 2013, 87:2969-2973.
35. Roberts A., Kretzschmar E., Perkins A.S., Forman J., Price R., Buonocore L., et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 1998, 72:4704-4711.
36. Reuter J.D., Vivas-Gonzalez B.E., Gomez D., Wilson J.H., Brandsma J.L., Greenstone H.L., et al. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol 2002, 76:8900-8909.
37. Kahn J.S., Roberts A., Weibel C., Buonocore L., Rose J.K. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 2001, 75:11079-11087.
38. Braxton C.L., Puckett S.H., Mizel S.B., Lyles D.S. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J Virol 2012, 84:3552-3561.
39. Geisbert T.W., Daddario-Dicaprio K.M., Geisbert J.B., Reed D.S., Feldmann F., Grolla A., et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008, 26:6894-6900.
40. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005, 11:786-790.
41. Spearman P. HIV vaccine development: lessons from the past and promise for the future. Curr HIV Res 2003, 1:101-120.
42. Wang M., Yue Y., Dong C., Li X., Xu W., Xiong S. Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis. Clin Vaccine Immunol 2013, 20:1743-1751.
43. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
44. Ball L.A., Pringle C.R., Flanagan B., Perepelitsa V.P., Wertz G.W. Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virol 1999, 73:4705-4712.
45. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789.
46. Ciuffreda D., Comte D., Cavassini M., Giostra E., Buhler L., Perruchoud M., et al. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur J Immunol 2008, 38:2665-2677.
47. Ma Y., Li J. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus. J Virol 2011, 85:2942-2952.
48. Kemball C.C., Flynn C.T., Hosking M.P., Botten J., Whitton J.L. Wild-type coxsackievirus infection dramatically alters the abundance, heterogeneity, and immunostimulatory capacity of conventional dendritic cells in vivo. Virology 2012, 429:74-90.
49. Kemball C.C., Harkins S., Whitmire J.K., Flynn C.T., Feuer R., Whitton J.L. Coxsackievirus B3 inhibits antigen presentation in vivo, exerting a profound and selective effect on the MHC class I pathway. PLoS Pathog 2009, 5:e1000618.
50. Dalton D.K., Haynes L., Chu C.Q., Swain S.L., Wittmer S. Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J Exp Med 2000, 192:117-122.
51. Badr G., Bedard N., Abdel-Hakeem M.S., Trautmann L., Willems B., Villeneuve J.P., et al. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol 2008, 82:10017-10031.
52. Lore K., Adams W.C., Havenga M.J., Precopio M.L., Holterman L., Goudsmit J., et al. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 2007, 179:1721-1729.
53. Ahmed M., Brzoza K.L., Hiltbold E.M. Matrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cells. J Virol 2006, 80:2194-2205.
54. Ahmed M., Mitchell L.M., Puckett S., Brzoza-Lewis K.L., Lyles D.S., Hiltbold E.M. Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms. J Virol 2009, 83:2962-2975.